兴兵地那非治疗勃起功能障碍（ED）

阴蒂外周（ED）症状更为比如说是可用Vardenafil（魏地那非）顺利完成治疗法对ED类固醇Sildenafil（西地那非）和Vardenafil（魏地那非）顺利完成比如说是比较科学实验，想需要给与无偏见的结果。波士顿-2006年9月初20日，统计分析结果刊出在《特质华尔街日报》上，同时在希腊开罗召开大会的特质医学国际协就会第十一届大就会上刊发。这项统计分析相当独特，因为其原始数据来自一项关于PDE5（磷酸二脂酶5）诱发类固醇的直接对比诊断次测试，该次测试可用PDE5诱发类固醇来治疗法ED症状。整个统计分析经过精心设计使得针对每种类固醇的偏见大幅提高成比则有。这是一项随机、双盲、交叉和直接对比的诊断次测试，可用西地那非和魏地那非治疗法患有ED、肝炎、高血压和/或高血脂的男特质症状，比较了二者的治果。表明在数个会用的有效特质就是指标上魏地那非取得了社会学意义上的优势，在病症状满意度和比如说是特质的多个审核检验里，魏地那非的体现并不比西地那非差。共有1，057名男特质参与了这项统计分析，他们首先年中四个月份服食一种类固醇，然后是一个月份月份的缓冲期，接着再年中四个月份服食另一种类固醇。病症状就会被问起这样的弊端：“总的来说是，你更为喜欢可用那种类固醇？”此外还有其他11个有关ED治疗法的弊端。借助于原本基准顺利完成另加有效特质审核在统计分析里也被可用。原始数据表明38.9%的病症状比如说是可用魏地那非，而34.5%的病症状不愿可用西地那非（26.6%的病症状无比如说是特质）。在阴蒂功能，满意度和总体满意度层面，魏地那非很大优于西地那非。在阴蒂时插入硬度，阴蒂维系月份，全程维系和阴蒂信心层面，魏地那非也有更为高比则有的阳特质质子化。这项统计分析的共同完成作者，特质华尔街日报的主编Irwin Goldstein 暗示说是：“该统计分析表明我们对PDE5诱发类固醇诊断区别的理解又前进了为最主要一步，肯定了魏地那非治疗法ED的。”迄今为止有三种PDE5诱发类固醇可用于治疗法ED，它们分别是西地那非，他达那非和魏地那非。根据统计分析者的来历，所有这三种类固醇对一定以外的人群都体现出有效特质和耐受特质。来自直接对比的诊断科学实验原始数据（如本项统计分析）相当稀少，然而这样的统计分析结果就会帮助诊断牙医对西地那非、魏地那非和他达那非加以区别以选择最适合的类固醇供幼体病症状可用。历史背景知识：ED：阴蒂外周 Erectile dysfunction, ED是就是指持续不用大幅提高或者维系阴蒂以受限制。ED比过去用的"阳萎"（Impotence）一词更为确切，因为阳痿一词带有一定歧特质的该词。ED可按其程度分为轻、里、为重三度，阳痿仅指为重度的ED。70七十年代后由于阴蒂生理和病关节炎统计分析的进展，人们确信固然人有确实可以引来ED，但对大多数男特质来说是，ED与许多哮喘（高血压，肝炎，心血管哮喘）、类固醇、眼部及动手术等有关，因为阴蒂程序是血管壁骨骼肌松弛，颈动脉扩展到张，血源减少和静脉回源受到影响等完整血液动力学每一次，在这一每一次里，任何外周的病关节炎可以分为： 器质特质ED 血管特质原因：之外任何也许导致血管壁颈动脉血源缩减的哮喘，如：颈动脉粥样硬化，颈动脉损伤，颈动脉陡峭，颈动脉分源及心功能出现异常等，或有碍静脉回源开口程序的白膜、很薄窦内骨骼肌缩减所致的静脉引。 神经细胞特质原因：里枢、外周神经细胞哮喘或损伤之外可以导致阴蒂外周。 动手术与眼部：大血管动手术、癌根治术、肩就会阴直肠癌根治术等动手术及骨盆小腿、腰椎压缩特质小腿或骑跨伤，可以引来起有关的血管和神经细胞损伤，导致阴蒂外周。 荷尔蒙疾患、慢特质病和长期服食某些类固醇也可以引来阴蒂外周。 本身哮喘：如硬结关节炎（Peyronie's disease）、平直畸形、严为重包茎和包皮家养胆。 无意识特质ED 就是指尴尬、担忧、躁郁关节炎、焦虑和夫妻感情不和等自觉人有所致使的阴蒂外周。 混合特质ED 就是指自觉人有和器质特质病关节炎共同完成导致的阴蒂外周。此外，由于器质特质ED仍未给与即时的治疗法症状无意识担忧加为重，害怕失败，使ED治疗法更为加方向发展精细。国内一组628则有ED症状病关节炎分类的统计分析表明：无意识特质占39%。器质特质为15.8%，混合特质占45.2%。PDE5药物PDE5是血管壁里骨骼肌钙离子第二信使NO-cGMP的分解酶。PDE5药物需要减少cGMP的沸点，增强血管壁骨骼肌的外周依赖性，并促进特质刺激诱发的阴蒂质子化。PDE5药物类类固醇对ED治疗法不具备最广泛的有效特质和耐受特质。因此，该类类固醇被看成制剂治疗法类固醇的参照基准。迄今为止，该类类固醇之外三种：西地那非、魏地那非和他达拉非。西地那非在1998年，魏地那非和他拉那非则是在2003年给与当今世界认证。在诊断可用以及诊断印证统计分析里发现，PDE5药物不具备不错的耐受特质和有效特质。在普通ED症状里，诊断统计分析确实推测上述三种类固醇的有效特质。 Study shows men with ED for treatment with Vardenafil Preference trial for ED drugs Sildenafil vs. Vardenafil attempts unbiased results BOSTON -- September 20, 2006 ?Research published in The Journal of Sexual Medicine and presented at the 12th World Congress of the International Society for Sexual Medicine in Cairo, Egypt is unique in that the data is from a head to head trial of PDE5 inhibitors used to treat patients with erectile dysfunction (ED), designed to minimize bias toward either study drug. The study was a randomized, double-blind, crossover, head-to-head clinical trial that compared vardenafil and sildenafil treatment in men with ED and diabetes, hypertension, and/or hyperlipidemia. The results demonstrated that vardenafil achieved nominal statistical superiority over sildenafil for several frequently used efficacy measures, and non-inferiority of vardenafil to sildenafil as measured by various assessments of patient satisfaction and patient preference. A total of 1,057 men participated in the study, which involved treatment using each drug for four weeks, with a one-week washout period in between. Patients were asked: "Overall, which medication do you prefer?" along with 11 other preference questions relating to their ED treatment. Additional efficacy assessments using established scales were also used in ysis. Data showed that 38.9% preferred vardenafil compared to 34.5% sildenafil (26.6% had no preference). Vardenafil was significantly superior to sildenafil in terms of erectile function, intercourse satisfaction and overall satisfaction. There were also a significant higher percentage of positive responses for vardenafil with regards to erection hardness for penetration, maintenance of erection, maintenance until completion, and erection confidence. "This study represents an important step forward in our understanding of the clinical differences between PDE5 inhibitors, confirming the efficacy of vardenafil for men with erectile dysfunction," explains Irwin Goldstein, study co-author and Editor-in-Chief of The Journal of Sexual Medicine. There are currently three PDE5 inhibitors ailable to treat ED: sildenafil, tadalafil and vardenafil, all of which he previously demonstrated efficacy and tolerability in a range of patient populations, according to researchers. Data from head-to-head clinical trials, like this one, are scarce. However, results from studies such as this should help clinicians to differentiate among sildenafil, vardenafil, and tadalafil and to select the most appropriate for individual patients.主编：bluelove

主编： Zhu